Collaboration and Research Arrangements |
9 Months Ended |
|---|---|
Sep. 30, 2024 | |
| Collaborative Arrangement Disclosure [Abstract] | |
| Collaboration and Research Arrangements |
3. Collaboration and Research Arrangements During the three and nine months ended September 30, 2023, the Company recognized revenue of $3.8 million and $9.6 million, respectively, under a license and collaboration agreement with Global Therapeutics, Inc, now a subsidiary of Pfizer. As the agreement was terminated in October 2023, no revenue was recognized during the three and nine month periods ended September 30, 2024. |
| X | ||||||||||
- Definition Collaborative Arrangement Disclosure [Abstract]. No definition available.
|
| X | ||||||||||
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|